Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

Rhea-AI Summary

Kiniksa Pharmaceuticals, Ltd. (KNSA) will host a conference call and live webcast on August 3, 2022, at 8:30 a.m. Eastern Time to discuss its Q2 2022 financial results and corporate activities. The live webcast will be available on the company's website, with a replay accessible about 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for significant unmet medical needs, with key portfolio assets including ARCALYST®, vixarelimab, KPL-404, and mavrilimumab.

Positive

• Kiniksa's portfolio focuses on therapeutic medicines for unmet medical needs.
• Assets targeted at underserved conditions may offer differentiation in the market.

Negative

• None.

HAMILTON, Bermuda, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, August 3, 2022, at 8:30 a.m. Eastern Time to report its second quarter 2022 financial results and corporate activities.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours of the event. The conference call can be accessed by dialing (800) 715-9871 (U.S. & Canada) or (646) 307-1963 (international) using conference ID number 1606846.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST^®, vixarelimab, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ^®

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com

FAQ

When will Kiniksa Pharmaceuticals report its Q2 2022 financial results?

Kiniksa Pharmaceuticals will report its Q2 2022 financial results on August 3, 2022.

How can I access the Kiniksa Pharmaceuticals conference call?

The conference call can be accessed by dialing (800) 715-9871 for U.S. and Canada or (646) 307-1963 internationally.

What is Kiniksa Pharmaceuticals' focus area?

Kiniksa Pharmaceuticals focuses on discovering and developing therapeutic medicines for debilitating diseases with significant unmet medical needs.